Clinuvel Pharmaceuticals vs Intellia Therapeutics
Clinuvel Pharmaceuticals and Intellia Therapeutics are similar in size: $64.3m and $67.7m of revenue in their latest fiscal years. Intellia Therapeutics grew faster (16.9% against 5.2%). Clinuvel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.0% against -609.9%. Clinuvel Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Clinuvel PharmaceuticalsCUVL, 2026 | Intellia TherapeuticsNTLA, 2025 |
|---|---|---|
| Revenue | $64.3m | $67.7m |
| Revenue growth | 5.2% | 16.9% |
| Net income | $23.2m | −$413m |
| Operating margin | 43.4% | -651.7% |
| Net margin | 36.0% | -609.9% |
| Return on equity | 13.4% | -53.5% |
| Free cash flow | $11.8m | −$396m |
| Cash | $13.9m | $155m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 377 |
| Market value | $256m | $1.65bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 18 sales |